https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Initiates-Pivotal-Phase-III-Program-for-IW-3718-in-Persistent-Gastroesophageal-Reflux-Disease/default.aspx
https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Initiates-Pivotal-Phase-III-Program-for-IW-3718-in-Persistent-Gastroesophageal-Reflux-Disease/default.aspx